Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07175441 · ClinicalTrials.gov registry record · Phase 2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
A Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 3
- Study locations
NCT07175441: Recruiting Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma, sponsored by Riboscience.
NCT07175441 is a Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by Riboscience. The registered enrollment target is 220 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07175441, a Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 3
- Study locations
Study Summary
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
Primary Outcome
Time in months from randomization until the first radiographic documentation of objective progression, as assessed using RECIST 1.1, or death from any cause.
Conditions Studied
Interventions
- DRUG RBS2418
- DRUG STRIDE (durvalumab + tremelimumab)
Study Locations (3)
Maryland
- Johns Hopkins - Baltimore
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- START Dallas Fort Worth - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT07175441 shows while recruiting
NCT07175441 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Advanced Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which RBS2418 is the first listed.
NCT07175441 reports a single indexed study location in Maryland, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT07175441 about?
NCT07175441 is a clinical study titled "Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma". RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-pre...
What is the current status of trial NCT07175441?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2026-04. Estimated completion is 2027-08.
What conditions does trial NCT07175441 study?
This clinical trial studies the following conditions: Advanced Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07175441?
The interventions under investigation include: RBS2418 (DRUG), STRIDE (durvalumab + tremelimumab) (DRUG).
Who is sponsoring clinical trial NCT07175441?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07175441 being conducted?
This trial has 3 study locations across Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07175441's enrollment target sits among peer trials
220 275th of 2000 higher than 1,719 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia